VERTEX PHARMACEUTICALS INC / MA (VRTX) – SEC staff letter
2026-04-14 · Re: Vertex Pharmaceuticals, Inc. Form 10-K for Fiscal Year Ended December 31, 2025 · Accession 0000000000-26-003732 · Review completed (no further comments)
April 14, 2026 Charles F. Wagner, Jr. Executive Vice President and Chief Operating & Financial Officer Vertex Pharmaceuticals, Inc. 50 Northern Avenue Boston, MA 02210 Re: Vertex Pharmaceuticals, Inc. Form 10-K for Fiscal Year Ended December 31, 2025 File No. 000-19319 Dear Charles F. Wagner Jr.: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life…
Full letter on EDGAR → · Filing index · All VERTEX PHARMACEUTICALS INC / MA (VRTX) correspondence
Templates & resources
- AICPA & CIMA – SEC reporting resources (AICPA & CIMA · Professional body · Free / member)
- BDO Accounting, Reporting & Compliance Hub (ARCH) (BDO · Firm guide · Free)
- Deloitte DART – Roadmap Series (Deloitte · Firm guide · Free)
- Deloitte Roadmap: SEC Comment Letter Considerations (Deloitte · Firm guide · Free)
- KPMG Financial Reporting View (KPMG · Firm guide · Free)
- PwC Viewpoint (PwC · Firm guide · Free / paid)
- RSM Financial Reporting Resource Center (RSM · Firm guide · Free)
- SEC – EDGAR Full Text Search (SEC · Regulator · Free)